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Abstract
Objectives To assess the safety and feasibility of MRI-guided
high-intensity focused ultrasound (MR-HIFU) ablation in
breast cancer patients using a dedicated breast platform.
Methods Patients with early-stage invasive breast cancer
underwent partial tumour ablation prior to surgical resection.
MR-HIFU ablation was performed using proton resonance
frequency shift MR thermometry and an MR-HIFU system
specifically designed for breast tumour ablation. The presence
and extent of tumour necrosis was assessed by histopatholog-
ical analysis of the surgical specimen. Pearson correlation co-
efficients were calculated to assess the relationship between
sonication parameters, temperature increase and size of tu-
mour necrosis at histopathology.
Results Ten female patients underwent MR-HIFU treatment.
No skin redness or burns were observed in any of the patients.
No correlation was found between the applied energy and the
temperature increase. In six patients, tumour necrosis was ob-
served with a maximum diameter of 3–11 mm. In these pa-
tients, the number of targeted locations was equal to the num-
ber of areas with tumour necrosis. A good correlation was
found between the applied energy and the size of tumour
necrosis at histopathology (Pearson=0.76, p=0.002).
Conclusions Our results show that MR-HIFU ablation with
the dedicated breast system is safe and results in histopatho-
logically proven tumour necrosis.
Key Points
• MR-HIFU ablation with the dedicated breast system is safe
and feasible
• In none of the patients was skin redness or burns observed
• No correlation was found between the applied energy and
the temperature increase
• The correlation between applied energy and size of tumour
necrosis was good
Keywords High-intensity focused ultrasound . Ablation .
Breast cancer .Magnetic resonance imaging .Minimally
invasive treatment
Introduction
Breast cancer is the most common malignancy among
women worldwide [1]. The disease is currently fre-
quently diagnosed at an early stage because of
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mammographic screening programmes and improved
awareness [2]. Over the past decades, breast cancer
treatment has evolved towards less invasive local treat-
ment. Breast-conserving therapy (BCT), i.e. lumpectomy
with additional radiotherapy, is currently standard-of-
care in patients with early-stage breast cancer and has
shown equal survival rates compared to radical mastec-
tomy [3, 4]. A range of minimally invasive techniques
holds promise for replacing lumpectomy by local breast
tumour ablation, for example cryoablation, radiofrequen-
cy ablation or microwave ablation. All these techniques,
however, require percutaneous insertion of a probe into
the breast tumour [5–7]. High-intensity focused ultra-
sound (HIFU) is a completely noninvasive technique
that can be used for thermal ablation in a target volume
deep within the body [8]. Imaging during minimally
invasive treatment is crucial to localize the target area
and monitor the treatment procedure. Magnetic reso-
nance imaging (MRI) offers excellent anatomical imag-
ing for treatment planning by defining the target volume
and organs at risk, is able to provide real-time temper-
ature monitoring during therapy, and allows direct eval-
uation of treatment results [9–11]. In 2001, Huber et al.
[12] described the first MRI-guided HIFU (MR-HIFU)
treatment in a breast cancer patient. Subsequently sever-
al groups reported on MR-HIFU ablation of malignant
breast tumours prior to surgical resection [13–16].
Overall, authors concluded that MR-HIFU ablation of
breast cancer was technically feasible. Complete tumour
necrosis, however, was achieved in only 20–50 % of
patients, whereas complete tumour ablation has to be
ensured before surgical resection can be omitted.
Optimizing these results is necessary for MR-HIFU
treatment to be considered as a clinically attractive al-
ternative to surgery for local breast tumour control.
In this study, we report the first experiences on tu-
mour ablation in breast cancer patients using an MR-
HIFU breast platform specifically designed for breast
tumour ablation [17]. In previous studies, treatments
were performed using MR-HIFU systems with a single
transducer targeting the breast from the anterior using a
point-by-point ablation method [13, 15]. In contrast,
with our dedicated platform, the breast is targeted
laterally, consequently reducing the risk of unintended
heating of the heart and lungs. In addition, the wide
transducer aperture decreases the local energy density
on the skin during ablation. Furthermore, a volumetric
ablation approach is used, resulting in larger and more
homogeneous ablation volumes and a reduction in
treatment duration [18, 19]. The aim of the current
study was to assess the safety and feasibility of tumour




The study protocol was approved by the institutional review
board of the University Medical Center Utrecht and written
informed consent was obtained from all patients. Patients were
recruited in the Diakonessenhuis Utrecht and included in the
University Medical Center Utrecht between September 2012
and June 2014. Inclus ion cr i te r ia were: women
aged>18 years; World Health Organization (WHO) perfor-
mance status≤2; body weight≤80 kg; clinically staged T1-
2, histopathologically proven invasive breast cancer.
Exclusion criteria were: neoadjuvant systemic therapy; con-
traindications for MRI; macro-calcifications; scar tissue or
surgical clips in the direct path of the ultrasound beams.
All patients underwent an MRI examination on a 3-T clin-
ical MR scanner (Achieva, Philips Healthcare, Best,
The Netherlands) to assess whether the following additional
inc lus ion c r i t e r i a were me t : max imum tumour
diameter≥ 1.0 cm; tumour location within the reach of the
HIFU transducers with the patient in prone position;
distance from skin and pectoral muscle to the centre of the
target≥1.0 cm.
Dedicated MR-HIFU breast platform
MR-HIFU ablation was performed using a dedicated MR-
HIFU breast platform (Sonalleve-based prototype, Philips
Healthcare, Vantaa, Finland) which was integrated into a
1.5-T MR scanner (Achieva, Philips Healthcare, Best,
The Netherlands). During MR-HIFU treatment, patients were
placed in prone position on the HIFU table top with the
targeted breast in the water-filled breast cup surrounded by
eight separate 32-element transducers distributed over a 270°
circular arc. The specifications of the system have been pre-
viously described in more detail [17]. In addition, Deckers




Patients were under procedural sedation during MR-HIFU
treatment. A team of procedural sedation and analgesia spe-
cialists monitored the cardiorespiratory functions and admin-
istered sedative agents and analgesics intravenously. In the
first two patients, procedural sedation was maintained using
continuous propofol infusion and an additional opioid analge-
sic prior to each sonication. Due to undesired patient motion
and variations in the breathing pattern during these first two
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treatments, a combination of propofol and esketamine was
used during all other treatments.
MR imaging
Figure 1 shows a schematic overview of the procedures and
MR pulse sequences during treatment. Treatment planning
was performed based on the localization of the breast tumour
on dynamic contrast-enhanced (DCE) MR imaging (dynamic
scan time 78.3 s; TR/TE 6.6/3.2 ms; flip angle 10°; turbo-
factor=36; acquisition voxel size 1.12×1.12×2.0 mm3; 140
slices; matrix size 304×180; SPIR fat suppression). One dy-
namic was acquired before and four dynamics were acquired
directly after injection of a gadolinium-based contrast agent
(GBCA) (0.1 ml gadobutrol/kg body weight (Gadovist, Bayer
Schering Pharma AG, Berlin, Germany)). Because of the po-
tential hazard of heating a GBCA inside the body, a waiting
time of 30 min was maintained between contrast injection and
the first sonication. Before each sonication, a short T1-
weighted scan was performed, which was visually compared
to T1-weighted images acquired at the beginning of the treat-
ment procedure to confirm accurate patient positioning.
During sonications, subtraction-based PRFS (proton reso-
nance frequency shift) MR thermometry using an echo planar
imaging (EPI) pulse sequence was performed with the follow-
ing parameters: TR/TE 70/30 ms; flip angle 20°; EPI-factor
23; acquisition voxel size 1.67×1.67×5.0 mm3; 4 slices; ma-
trix size 96×92; composite RF pulse fat suppression. Four
planes were monitored with a temporal resolution of 2.25 s:
a coronal and sagittal slice through the focal point, a coronal
near-field slice positioned 9.5 mm anterior to the focal point,
and a far-field slice manually positioned at the pectoral mus-
cle. A look-up-table (LUT)-based correction method was used
to correct errors in the MR temperature maps caused by
respiration-induced magnetic field disturbances [20, 21].
Relative temperature maps were calculated on the fly and
overlaid onto T1-weighted, fat-suppressed magnitude images
of the thermometry sequence. In patients three to ten, 160 mg/
L MnCl2∙4H2O was added to the water in the breast cup to
shorten its T2 signal and prevent ghosting artefacts duringMR
thermometry due to possible subtle motion of the water in the
breast cup. The same DCE-MR scan that was used for treat-
ment planning was repeated directly after MR-HIFU ablation
for treatment evaluation.
High-intensity focused ultrasound ablation
In this first study with the MR-HIFU breast platform, partial
tumour ablation was performed to be able to analyze the lo-
cation and size of separate sonications and to assess the rela-
tionship between different sonication parameters and the size
of tumour necrosis at histopathology. Low energy test sonica-
tions were performed prior to therapeutic sonications to verify
the focal spot position. A correction was performed in case of
spatial misalignment. Test sonications were 3-mm treatment
cells with low (20–40 W) acoustic power. Therapeutic soni-
cations were performed using a volumetric ablation technique
with concentric circular trajectories of increasing size [18].
The resulting treatment cells, i.e. the differently sized ablation
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3×2×2 mm3 or 6×4×4 mm3 (size of the volume bound by
the iso-intensity surface at −6 dB of the peak value in the
centre) and a sonication duration of 20 and 24.5 s, respective-
ly. The applied acoustic power during therapeutic sonications
varied between 50 and 100 W with a frequency of 1.45 MHz.
Multiple sonications were allowed at one or more locations
within tumours. Each sonication was followed by a period of
cooling. Sonications were aborted when temperatures≥80 °C
were observed in the MR temperature maps. Note that such
apparent temperature elevations are not necessarily real, since
the occurrence of artefacts (due to breathing or patient motion)
may corrupt temperature measurements and lead to erroneous
observation of excessive temperatures.
After MR-HIFU treatment
After MR-HIFU treatment, patients were admitted to a clinical
ward for a minimum of 3 h to ensure stable haemodynamic
function. Surgery was performed within 48 h and 10 days after
MR-HIFU treatment. Clinical management of the axilla was
performed according to standard clinical guidelines by a sen-
tinel lymph node biopsy (SLNB) or axillary lymph node dis-
section. After surgical resection, tissue was submerged in for-
malin. The excised tissue containing the tumour was dissected
into slices of approximately 5 mm. Microscopic sections of
4 μm were cut and stained with haematoxylin and eosin
(H&E) for histological analysis.
Safety and feasibility
After MR-HIFU treatment, the skin of the treated breast was
evaluated by a physician for the presence of skin burns or
redness. Patients were asked to report pain scores according
to the numerical rating scale, with a score of 0 (no pain) to 10
(worst pain imaginable) [22]. Monitoring of adverse events
was done until surgery. A radiologist compared the DCE-
MRI before and after MR-HIFU ablation to assess the pres-
ence of non-perfused volumes (NPVs) after ablation. For each
sonication, the maximum temperature was reported based on
the median temperature evolution in nine pixels in the centre
of mass of the heating at the end of sonications. In addition,
the maximum diameter of the area that reached a temperature
higher than 55 °Cwas reported. All analyses were done for the
coronal MR thermometry slice using software developed in
Matlab (Mathworks, Natick, MA, USA).
For all performed sonications, the relationship between the
duration and power of sonications and the temperature in-
crease from baseline temperature as measured by MR ther-
mometry was assessed using simple linear regression analy-
ses. In addition, the correlation between duration, applied
powers, temperature increase and the size of tumour necrosis
at histopathologywas investigated for each sonicated location.
A Pearson correlation coefficient (r) < 0.25 was considered to
indicate a trivial correlation, between 0.25 and 0.5 a low cor-
relation, between 0.51 and 0.75 a medium correlation,
and>0.76 a high correlation. A p-value≤0.05 was considered
to be significant.
A dedicated breast pathologist evaluated the presence and
the size of the areas with tumour necrosis, which were manu-
ally delineated using Aperio ImageScope (Leica
Microsystems, Rijswijk, The Netherlands).
Results
Patients
Seventeen patients were initially enrolled in the study. In five
patients, an additional lesion was detected at pre-treatment
MRI. Two of these patients were excluded due to logistical
reasons because of additional diagnostic work-up, and three
patients withdrew from the study themselves. In addition, two
patients withdrew from the study because of fear of an epilep-
tic insult during MR-HIFU treatment (n=1) and claustropho-
bia (n=1). Finally, ten patients underwent MR-HIFU treat-
ment. Table 1 lists the demographic data of these patients.
MR-HIFU treatment
The overall duration of MR-HIFU treatment was on average
145min. The actual sonication timewas 1.7 min (Table 2). An
overview of the performed sonications per individual patient
is provided in Table 3. In the first and third patients, only one
therapeutic sonication was performed. These were both
aborted in an early phase due to the erroneous measurement
of excessive temperatures caused by patient motion or a
change in the breathing pattern. In the second patient, three
of four therapeutic sonications were prematurely aborted (at
60.8 %, 90.2 % and 98.5 % of the full sonication length) for
the same reasons. In patients four to ten, 23 of 24 (95.8 %)
therapeutic sonications were fully executed.
Safety
No skin redness or burns were observed in any of the patients.
Patient seven developed three small white lumps with a max-
imum diameter of 0.5–1.5 cm on the skin of the treated breast
in the days after MR-HIFU treatment. Histopathological anal-
ysis of a biopsy from one of these lumps showed no signs of
abnormal tissue. Over time, the lumps resolved without inter-
vention. Other minor adverse events were nausea and
vomiting (in two patients) in the hours after treatment, proba-
bly related to the administered anaesthetics. After MR-HIFU
treatment, eight patients reported no pain. The other two pa-
tients reported a pain score of 4 and 5, respectively.
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Treatment results
No visual differences were observed between contrast-
enhanced MRI before and after MR-HIFU ablation. In pa-
tients in whom valid thermometry data were acquired
(n=7), the average maximum temperature of therapeutic son-
ications was 51.4 ± 5.7 °C (range 40.4–61.4 °C). Figure 2
shows an example of MR thermometry images during a
sonication.
For the 33 of 47 performed sonications with adequate MR
thermometry data, no relationship was found between the du-
ration or applied power of the sonications and the temperature
increase. In addition, no correlation was found between the
product of duration and power (i.e. the applied energy) and
the temperature increase (Fig. 3). In particular between different
patients, the acoustic powers required to achieve a certain in-
crease in temperature varied considerably. For example, the
maximum temperature in patient four was about 59 °C during
50-W sonications, whereas the maximum temperature in pa-
tient eight remained below 55 °C during three 80-W sonica-
tions. Within an individual patient, the peak temperature was
more dependent on the applied acoustic power, e.g. for increas-
ing powers, higher maximum temperatures were observed.
The maximum diameter of the area with a temperature
higher than 55 °C varied between 3 and 15 mm. In patient
six, no temperatures above 55 °C were observed on the coronal
MR thermometry slice. In contrast, a maximum temperature of
58.5 °C was measured during the second 70-W sonication in
the sagittal slice. In patient nine, a mild temperature increase of
about 1 cm anterior of the focal point was measured, whereas
no temperature data were acquired in the actual focal point.
Histopathology
In six of ten patients, tumour necrosis was observed after MR-
HIFU ablation by the presence of tissue coagulation and leak-
age of erythrocytes at H&E staining (Fig. 4). The maximum
diameter of tumour necrosis varied from 3 to 11 mm (Table 4).
Patient four refused to undergo surgery. In patients one, seven
and nine, no tumour necrosis was observed. In patient one, only
one therapeutic sonication was performed, which was aborted
shortly after its initiation. In patient seven, sonications were
mainly located in the adipose tissue anterior to the tumour be-
cause the tumour eventually turned out to be just outside the
range of the transducers. No necrosis was observed inside the
tumour; however, fat cell necrosis was observed in the adipose
tissue anterior to the tumour. Also in patient nine, the focal point
was located outside the tumour, which was caused by an incor-
rect misalignment correction after the test sonication.
Table 1 Baseline characteristics of breast cancer patients who
underwent MRI-guided high-intensity focused ultrasound (MR-HIFU)
treatment
Patients n (%)
No. of patients 10
Age in years, mean ± SD 54.8 ± 12.5
Treated tumours
Tumours in right breast 6 (60.0)
Tumour location
Upper outer quadrant 3 (30.0)
Lower outer quadrant 5 (50.0)
Upper inner quadrant 2 (20.0)
Lower inner quadrant 0 (0.0)
Interval between HIFU and surgery




No surgery 1 (10.0)
Axilla
Sentinel lymph node procedure 8 (80.0)
Axillary dissection 1 (10.0)
No axillary procedure 1 (10.0)
Pathology
Tumour size in mm, mean ± SD 20.0 ± 5.6*
Type carcinoma
Invasive ductal carcinoma 8 (80.0)
Invasive lobular carcinoma 2 (20.0)
*Analyzed without the patient who refused surgery




Stage of the procedure Time in min, mean ± SD (range)
Positioning on treatment table
(including MR imaging until contrast injection)
25± 10 (5–39)
Pre-treatment imaging from contrast injection to the first (test) sonication 59± 27 (32–106)
Treatment time (from first to last sonication) 46± 17 (12–75)
Post-treatment imaging after the last sonication 14± 3 (7–19)
Overall procedure time 145 ± 29 (96–210)
Overall sonication time 1.7 ± 0.8 (0.3–2.6)
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Table 3 An overview of the
sonications, size, power, duration
of sonications, maximum
temperature and size of the area(s)
that reached a temperature higher
than 55 °C for all patients
Patient Sonication Size (mm) Power (W) Duration (s) Max temp (°C) Temp > 55 °C (mm)
1 1 (test) 3 30 8.5* NA† NA†
2 6 100 8.6*
2 1 (test) 3 30 16.1* NA† NA†
2 3 70 19.7*
3 (test) 3 30 12.3*
4 6 60 14.9*
5 6 50 24.6
6 6 70 22.1*
3 1 (test) 3 40 12.9* 56.1 10 × 7
2 6 70 16.8* 52.6 3 × 3
4 1 (test) 3 40 20.2 55.7 5 × 5
2 6 50 24.6 59.0 3 × 2
3 6 50 24.6 58.3 7 × 5
4 6 50 24.6 59.1 5 × 3
5 1 (test) 3 40 20.0 NA‡ NA‡
2 (test) 3 40 20.0 NA‡ NA‡
3 (test) 3 40 20.0 55.7 8 × 7
4 (test) 3 30 20.0 51.1 No
5 6 50 24.5 61.4 15 × 12
6 6 60 23.2* 57.9 12 × 10
7 6 50 24.5 56.4 8 × 7
6 1 (test) 3 30 20.1 45.8 No
2 6 50 24.6 49.4 No
3 6 60 24.6 50.3 No
4 6 70 24.6 52.7 No
5 6 70 24.6 51.6 No
7 1 (test) 3 30 20.1 NA§ NA§
2 3 50 20.1
3 6 70 24.6
4 6 90 24.6
8 1 (test) 3 30 20.1 43.9 No
2 6 60 24.6 48.0 No
3 6 80 24.6 46.8 No
4 6 60 24.6 49.1 No
5 6 80 24.6 48.8 7 × 5
6 6 80 24.6 51.9 5 × 2
9 1 (test) 3 40 20.1 43.2 No
2 6 60 24.6 42.5 No
3 6 80 24.6 42.7 No
4 6 80 24.6 40.4 No
5 (test) 3 40 20.1 42.7 No
6 6 80 24.6 46.7 No
10 1 (test) 3 30 20.1 45.5 No
2 (test) 3 40 20.1 46.6 No
3 (test) 3 40 20.1 44.0 No
4 6 80 24.6 54.4 No
5 6 80 24.6 51.7 7 × 7
NA not available
* Sonication was prematurely terminated due to an incorrect excessive heating abort
† The quality of the thermometry data was too low for any valid temperature estimates
‡ During the first two sonications in this patient, the fat signal was not suppressed during RPFS thermometry. No
valid thermometry data were acquired
§ Sonications were mainly located in the adipose tissue anterior of the tumour and no valid thermometry data
were acquired
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Sonications were performed at 19 different locations: one to
four different locations per patient. In the six patients with tu-
mour necrosis, the number of targeted locations was equal to
the number of areas with tumour necrosis at histopathology. In
these patients, sonications were performed at 13 different loca-
tions, corresponding to 13 different areas of tumour necrosis.
Correlation between sonication parameters and the size
of tumour necrosis at histopathology
For these analyses, patients four (no histopathology available),
seven and nine (sonications located in adipose tissue) were
excluded, yielding 14 different locations. Amedium correlation
was found between the duration of sonications (r = 0.73,
p=0.003) and the applied acoustic power (r=0.62 p=0.019),
and the size of tumour necrosis at histopathology. Furthermore,
a good correlation was found between the applied energy and
the size of tumour necrosis at histopathology (r = 0.76,
p=0.002, Fig. 5). For 11 locations, adequate MR thermometry
data were available. No relationship was found between the
temperature increase and the size of tumour necrosis at histo-
pathology. Furthermore, no correlation was found between the
size of the area with a temperature higher than 55 °C and the
size of tumour necrosis at histopathology. The product of the
duration and the temperature increase and the size of tumour
necrosis showed a medium correlation (r=0.74, p=0.01).
Fig. 2 Magnitude images (grey scale) overlaid with MR thermometry
data (colour-coded) during the seventh sonication in patient five; a 50-W
sonication with a duration of 24.5 s. The maximum temperature reached
during this sonication was 56.4 °C. Figures a–d and e–h show the coronal
and sagittal images through the focal point, respectively, which were























Duration (s) x applied power (W)
Fig. 3 Product of the duration (in
seconds) and the applied power
(in Watts) of the performed
sonications (i.e. the applied
energy) versus the increase in
temperature (in °C) as measured
with MR thermometry
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Discussion
Our results show that MR-HIFU ablation in breast cancer pa-
tients with the dedicated breast system is safe and feasible. In
none of the patients was skin redness or burns observed. A
good correlation was found between the product of duration
and power of sonications (i.e. the applied energy) and the size
of tumour necrosis at histopathology (r = 0.76, p = 0.002).
Furthermore, in the patients with tumour necrosis at histopa-
thology, the number of targeted locations was equal to the
number of areas with tumour necrosis.
No relationship was found between the applied energy and
the increase in temperature. Particularly between different pa-
tients, we observed that the acoustic powers required to
achieve a certain increase in temperature varied considerably.
This may be explained by differences in tumour perfusion and
patient characteristics, for example breast size or the ratio
between glandular and adipose tissue. Another factor
influencing the extent of temperature increase is the distance
between tumour and ultrasound transducers. In our system,
the circular arc of transducers covers 270°. If the targeted area
is close to the ‘open’ part of the arc of transducers, higher
powers may be needed to achieve the same increase in tem-
perature. Lastly, the measured temperatures are largely depen-
dent on the position of the MR thermometry slices. During
certain treatments (e.g. patients six and nine), the measured
temperature increase was not as high as one would expect
based on other treatments (e.g. patients four and five). This
was caused by an incorrect misalignment correction after the
test sonication due to the limited experience of the operator,
whereby the MR thermometry slice was not positioned exact-
ly through the focal point during the therapeutic sonications.
No relationship was found between the temperature in-
crease and the size of tumour necrosis or the size of the area
with a temperature higher than 55 °C and the size of tumour
necrosis at histopathology. This may be explained by the rea-
sons given before. A medium correlation was found between
the product of the duration of sonications and the temperature
increase, and the size of tumour necrosis at histopathology.
This result, however, has to be considered carefully because
it is a very simplified estimation of the complicated relation-
ship between time and temperature [23]. Unfortunately, we
were not able to calculate the exact thermal dose with our data.
Another limitation of our analyses is that pathology specimens
were not reconstructed in 3D. This means that the maximum
diameter used as the outcome measure for the size of tumour
necrosis is only an estimate of the whole area of tumour
necrosis.
This study was designed to investigate the safety and fea-
sibility of the dedicated MR-HIFU breast platform. Therefore,
we chose to allow patients with tumours between 3 and 5 cm
in size to participate in this study. Patients with large T2 tu-
mours, however, are generally not appropriate candidates for
treatment with minimally invasive ablation techniques such as
HIFU [17, 24]. In addition, the partial ablation design of our
study is different to that of previous studies. In our opinion,
this design is more suitable for investigating safety, e.g.
through the possibility of analyzing the location and size of
separate sonications. In addition, the relationship between dif-
ferent sonication parameters and the size of tumour necrosis at
Fig. 4 Macroscopic (a) and
microscopic pictures (b–d) of
the surgical specimen of the fifth
patient. (a) The yellow tissue is
adipose tissue and the white tissue
is the tumour tissue. The red-
brown area inside the tumour in-
dicates the presence of a
haemorrhagic area which is
caused by MRI-guided high-in-
tensity focused ultrasound (MR-
HIFU) ablation. (b–d)
Haematoxylin and eosin (H&E)
stainings with increasing magni-
fication. The blue line delineates
the invasive tumour which is
surrounded by normal
fibroglandular tissue and adipose
tissue. The area of tumour necro-
sis is encircled by a black line
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histopathology could be analyzed for all different locations.
Finally, the partial ablation approach allowed us to compare
viable versus ablated tumour tissue at histopathology and the
non-ablated tumour tissue could be used for the decision about
adjuvant treatments.
One of the shortcomings of MR-HIFU ablation in general
is the long duration of the procedure [25]. In our study, the
overall procedure time was on average 145 min, while the
actual sonication time was only 1.7 min. The most time-
consuming aspects of the treatment procedure were the
waiting time after contrast injection, filling of the LUT before
every sonication and the delays caused by the need to find a
proper navigator signal forMR thermometry. In future studies,
the ratio between the actual sonication time and the overall
procedure time has to be changed. We chose to treat patients
under procedural sedation because of the long duration of
treatment in an uncomfortable position. In addition, a regular
breathing pattern is preferable for LUT-based corrected MR
thermometry. In the first two patients, no valid thermometry
data were acquired due to artefacts caused by patient motion
and changes in breathing pattern. Consequently, most sonica-
tions were prematurely aborted automatically for safety rea-
sons. From patient three onwards, the sedation regimen was
changed to esketamine, a sedative agent with minimal impact
on respiration. In addition, the sedation specialists gained
more experience and gradually increased the dose of analge-
sics. In patients four to ten, no patient motion or changes in
breathing pattern were observed anymore and almost all ther-
apeutic sonications could be fully executed. An additional
problem during the first two treatments was the occurrence
of ghosting artefacts during MR thermometry, and conse-
quently MnCl2∙4H2O was added to the water in the breast
cup. Thereafter, no such artefacts were observed anymore.
In our study, we did not observe NPVs immediately after
MR-HIFU ablation. In other lesions, for example in benign
uterine fibroids, it is known that the observed NPV directly
after treatment is related to necrosis [19, 26]. Our results indi-

























Duration (s) x applied power (W)
Fig. 5 Product of the duration (in
seconds) and the applied power
(in Watts) of the performed
sonications (i.e. the applied
energy) versus the size of tumour
necrosis (in mm2) at
histopathology
Table 4 An overview of the sonications, locations and tumour necrosis for
all patients
Patient Sonication Location Tumour necrosis (mm)
1 1–2 1.1 No
2 1–2 2.1 3 × 1
3–6 2.2 7 × 3
3 1 3.1 5 × 2
2 3.2 6 × 4*
4 1–4 4.1 NA†
5 1–3 5.1 7 × 6
4–7‡ 5.2 10 × 5
6 1–5 6.1 11 × 7§
7 1–4 7.1 No
8 1–3 8.1 8 × 3
4 8.2 4 × 3
5 8.3 9 × 5
6 8.4 7 × 4
9 1–3 9.1 No
4 9.2 No
5–6 9.3 No
10 1–4 10.1 9 × 4
5 10.2 7 × 3
NA not available
* The thermal damage is for the major part present in the glandular tissue
outside the tumour due tomovement of the patient after the test sonication
† No pathology results available
‡ Treatment cells were positioned next to each other and not exactly at the
same location
§ Two other small areas of tumour necrosis were observed
No necrosis was observed inside the tumour; however, fat cell necrosis
was observed in the adipose tissue surrounding the tumour
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may show slow enhancement directly after MR-HIFU abla-
tion even when there is no evidence for residual tumour at
histopathology. This is in agreement with findings reported
by previous groups [27] and may be caused by leakage of
contrast into the interstitial space after tumour ablation. In
addition, we ablated only a small region within a large tumour
and no high-temporal resolution DCE-MRI was performed.
In conclusion, we report our first experiences with
MR-HIFU ablation of breast cancer using a dedicated breast
platform, concluding that MR-HIFU ablation is safe and re-
sults in histopathologically proven tumour necrosis.
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